Skip to content

Celcuity CELC Net Investment in Lease

Net Investment in Lease at other companies

BridgeBio Pharma logo
BridgeBio PharmaBBIO
Relay Therapeutics, Inc. logo
Relay Therapeutics, Inc.RLAY
Cogent Biosciences, Inc. logo
Cogent Biosciences, Inc.COGT
Tango Therapeutics logo
Tango TherapeuticsTNGX
CG Oncology logo
CG OncologyCGON
CRISPR Therapeutics logo
CRISPR TherapeuticsCRSP

Other financials

Income statement

See full
Operating income-$50.5M-39.8%
Net income-$52.8M-42.8%
EPS (diluted)-$0.97-12.8%

Balance sheet

See full
Cash & equivalents$145.2M+781%
Total debt$137.9M+30.7%
Total equity$53.5M-38.2%
Total assets$410.2M+88.0%

Cash flow

See full
Operating cash flow-$55.1M-53.6%
CapEx$249.0K+315%
Free cash flow-$55.3M-54.0%

Valuation

See full
Market cap$4.4B+1,370%

Returns & leverage

See full
Return on equity-275.2%-990pp
Debt / equity2.6×+1.4×
Current ratio12.3×+5.7×

Where this comes from

Reported directly by Celcuity in its filing.

Tagged under the XBRL concept us-gaap:OperatingLeaseRightOfUseAsset.

The official record: Celcuity’s 10-Q, filed May 14, 2026, on SEC EDGAR. View the filing →

Ask your AI about Celcuity's net investment in lease.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Celcuity's net investment in lease?
Celcuity (CELC) reported net investment in lease of $13K in Q1 2026.
How has Celcuity's net investment in lease changed year-over-year?
Celcuity's net investment in lease decreased by 92.4% year-over-year, from $172K to $13K.
What is the long-term trend for Celcuity's net investment in lease?
Over 5 years (2020 to 2025), Celcuity's net investment in lease has grown at a -26.1% compound annual growth rate (CAGR), from $230.91K to $51K.